Key facts
- TernaryTx’s last known valuation is $1.1M (Feb 2025).
- It has raised $5.5M; the latest was Early Stage VC ($4.8M) in Mar 2026.
- Notable investors include UK Innovation & Science Seed Fund, Daphni, Pace Ventures, i&i Biotech Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for TernaryTx
- ·The full record, as it builds
Funding rounds
No funding rounds for TernaryTx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TernaryTx
Developer of an AI-driven drug discovery platform designed for molecular glue therapeutics. The company's platform integrates multiple computational techniques to identify hot spots for ternary complex formation on protein surfaces and accelerates the identification of high-potential molecular glues, enabling the healthcare industry to reduce drug discovery timelines and increase success rates for immunological disorders.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 8
- Website
- ternarytx.co.uk/
- Ownership
- Privately Held (backing)
TernaryTx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TernaryTx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TernaryTx in its N-PORT filings yet. We sweep new filings monthly.